106928-09-0

Basic information

• Product Name: (1S, 9S)-9-[[(R)-1-Ethoxycarbonyl-3-phenylpropyl] amino]-10-oxo-octahydro-6H-pyridazino [1,2-a][1,2] diazepine-1-carboxylic acid
• Synonyms: Cilazapril EP impurity D;(1S, 9S)-9-[[(R)-1-Ethoxycarbonyl-3-phenylpropyl] amino]-10-oxo-octahydro-6H-pyridazino [1,2-a][1,2] diazepine-1-carboxylic acid
• CAS NO: 106928-09-0
• Molecular Formula: C22H31N3O5
• Molecular Weight: 417.49864
• Product Categories: Cilazapril
• Mol File: 106928-09-0.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (1S, 9S)-9-[[(R)-1-Ethoxycarbonyl-3-phenylpropyl] amino]-10-oxo-octahydro-6H-pyridazino [1,2-a][1,2] diazepine-1-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (1S, 9S)-9-[[(R)-1-Ethoxycarbonyl-3-phenylpropyl] amino]-10-oxo-octahydro-6H-pyridazino [1,2-a][1,2] diazepine-1-carboxylic acid(106928-09-0)
• EPA Substance Registry System: (1S, 9S)-9-[[(R)-1-Ethoxycarbonyl-3-phenylpropyl] amino]-10-oxo-octahydro-6H-pyridazino [1,2-a][1,2] diazepine-1-carboxylic acid(106928-09-0)

Safety Data

• Hazardous Substances Data: 106928-09-0(Hazardous Substances Data)

Upstream product

• 88784-33-2 (2S)-4-benzyloxicarbonyl-2-phthalimidobutanoic acid 
• 106928-72-7 (1S,9S)-t-butyl 1,2,3,4,7,8,9,10-octahydro-6,10-dioxo-9-phthalimidopyridazino<1,2-a><1,2>diazepine-1-carboxylate 
• 106927-97-3 (1S,9S)-t-butyl octahydro-10-oxo-9-phthalimido-6H-pyridazino<1,2-a><1,2>diazepine-1-carboxylate 
• 72064-51-8 (3S)-N¹-benzyloxycarbonyl-piperazic acid tert-butyl ester 
• 106860-13-3 (S)-2-[(S)-4-Benzyloxycarbonyl-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-butyryl]-tetrahydro-pyridazine-1,3-dicarboxylic acid 1-benzyl ester 3-tert-butyl ester 
• 88767-18-4 (S,S)-5-(6-(tert-butoxycarbonyl)tetrahydropyridazin-1(2H)-yl)-4-(1,3-dioxoisoindolin-2-yl)-5-oxopentanoic acid 
• 88767-16-2 (S)-4-Chlorocarbonyl-4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-butyric acid benzyl ester 
• 106860-20-2 9-amino-octahydro-10-oxo-6H-pyridazo[1,2-a][1,2]diazepine-1-(S)carboxylic acid t-butyl ester 
• 88767-98-0 ethyl (R)-4-phenyl-2-<<(trifluoromethyl)sulfonyl>oxy>butyrate 
• 90315-82-5 ethyl (R)-2-hydroxy-4-phenylbutyrate 
• 29678-81-7 (R)-2-hydroxy4-phenylbutanoic acid 
• 106860-19-9 (1S,9S)-t-butyl 9-<(1S)-ethoxycarbonyl-3-phenylpropylamino>octahydro-10-oxo-6H-pyridazino<1,2-a><1,2>diazepine-1-carboxylate 

Downstream Products

• 90139-06-3 cilazaprilat 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF AN INTERMEDIATE OF CILAZAPRIL

The present invention relates to a process for the preparation of optically pure (S,S)-6-t-butoxycarbonyl-hexahydro-1-pyridazinylcarbonyl-1,3-dioxo-2-isoindolebutyric acid, an intermediate for the preparation of cilazapril.

ENANTIOMERICALLY PURE CILAZAPRIL,PROCESS FOR PREPARATION

The invention relates to enantiomerically pure cilazapril and a process for preparing enantiomerically pure cilazapril. The invention also relates to pharmaceutical compositions that include the enantiomerically pure cilazapril and use of said composition

Pyridazo[1,2-a][1,2]diazepines

Novel compounds of the formula STR1 wherein B represents a methylene, ethylene or vinylene group, R1 represents a hydrogen atom or an alkyl, aralkyl, amino-alkyl, mono-alkylamino-alkyl, dialkylaminoalkyl, acylamino-alkyl, phthalimido-alkyl, alkoxycarbonylamino-alkyl, aryloxycarbonylamino-alkyl, aralkoxycarbonylamino-alkyl, alkylaminocarbonylamino-alkyl, arylaminocarbonylamino-alkyl, aralkylaminocarbonylamino-alkyl, alkylsulphonylamino-alkyl or arylsulphonylamino-alkyl group, R2 represents a carboxyl, alkoxycarbonyl or aralkoxycarbonyl group or a group of the formula STR2 R3 represents a carboxyl, alkoxycarbonyl or aralkoxycarbonyl group, R4 and R5 each represent a hydrogen atom or R4 and R5 together represent an oxo group, R6 and R7 each represent a hydrogen atom or an alkyl or aralkyl group or R6 and R7 together with the nitrogen atom to which they are attached represent a 5-membered or 6-membered heteromonocyclic ring which may contain a further nitrogen atom or an oxygen or sulphur atom, and n stands for zero, 1 or 2, and pharmaceutically acceptable salts thereof have antihypertensive activity and can be used as medicaments in the form of pharmaceutical preparations.